Gupta AA, et al. - Researchers conducted this single-center retrospective study to assess the long-term safety and effectiveness of intrastromal bevacizumab (0.05–0.1 mL of 2.5 mg/0.1 mL) for treatment of deep corneal neovascularization in participants for high-risk cornea grafting. The sample consisted of 14 patients (14 eyes) with chronic deep corneal neovascularization, treated with intrastromal bevacizumab by a single provider from 2011 to present. Intrastromal bevacizumab has been administered every 4–8 weeks. According to results, 64.2% of individuals had neurotrophic keratitis secondary to herpes zoster or simplex. It was concluded that intrastromal bevacizumab seems to be a safe and effective modality in the treatment of chronic corneal neovascularization, providing durable regression of corneal neovascularization and allowing for durable success of subsequent corneal transplants in patients at high risk. Minimal adverse effects have been noted.